Results 21 to 30 of about 118,558 (284)

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis : 48-week results from the EMBARK study [PDF]

open access: yes, 2015
Objective: To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA).
Bonin, Randi   +15 more
core   +1 more source

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

open access: yesArthritis care & research, 2019
To update evidence‐based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).
M. Ward   +22 more
semanticscholar   +1 more source

Ankylosing spondylitis: how does it affect the quality of life?

open access: yesLiječnički vjesnik, 2023
Ankylosing spondylitis is a progressive and debilitating disease known to immensely affect the quality of life and frequently cause disability. There are several instruments that measure this effect, such as Bath Ankylosing Spondylitis Disease Activity ...
Eva Perak   +3 more
doaj   +1 more source

Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice [PDF]

open access: yes, 2009
The SpAs are a group of overlapping, chronic, inflammatory rheumatic diseases including AS, a chronic inflammatory disease primarily affecting the SI joints.
Elewaut, Dirk, Matucci-Cerinic, Marco
core   +1 more source

Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review [PDF]

open access: yes, 2019
Adherence is a primary determinant of the effectiveness of any intervention. Exercise is considered essential in the management of spondyloarthritis (SpA); however, the overall adherence to exercise programmes and factors affecting adherence are unknown.
Coulter, EH   +4 more
core   +2 more sources

Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

open access: yesRheumatology, 2020
OBJECTIVE The aim of this study was to compare patients with ankylosing spondylitis with psoriasis (ASP) and without psoriasis (AS), to axial PsA (axPsA) patients. METHODS Two adult cohorts were recruited from the AS clinic: ASP and AS.
J. Feld   +6 more
semanticscholar   +1 more source

Ankylosing Spondylitis and the Risk of Lung Cancer: A Meta-Analysis and Mendelian Randomization

open access: yesFrontiers in Genetics, 2022
Background: It remains uncertain whether ankylosing spondylitis is associated with an increased risk of lung cancer.Methods: We conducted a meta-analysis to comprehensively evaluate the correlation between ankylosing spondylitis and lung cancer based on ...
Yiyuan Ao   +15 more
doaj   +1 more source

Establishing a Causal Link between Ankylosing Spondylitis and Inflammatory Bowel Disease: A Review of the Literature

open access: yesInternational Journal of Medical Students, 2016
The link between ankylosing spondylitis and inflammatory bowel disease is unclear, however it is hypothesized that there is a causal link between the inheritance of a human leukocyte antigen B27 allele and the development of inflammatory bowel disease ...
Jaclyn Rivington, Michael Gillett
doaj   +1 more source

Ankylosing spondylitis: etiology, pathogenesis, and treatments

open access: yesBone Research, 2019
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion.
Wei Zhu   +8 more
semanticscholar   +1 more source

Persistent clinical efficacy and safety of anti-tumour necrosis factor \textgreeka therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response [PDF]

open access: yes, 2008
Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS).
Alten, R.   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy